Graham Parry analyst BAML

Currently out of the existing stock ratings of Graham Parry, 3 are a HOLD (37.5%), 1 are a SELL (12.5%), 4 are a BUY (50%).

Graham Parry

Work Performance Price Targets & Ratings Chart

Analyst Graham Parry, currently employed at BAML, carries an average stock price target met ratio of 33.33% that have a potential upside of 50.06% achieved within 1979 days.

Graham Parry’s has documented 14 price targets and ratings displayed on 2 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NVS, Novartis AG ADR at 11-Sep-2024.

Wall Street Analyst Graham Parry

Analyst best performing recommendations are on NVS (NOVARTIS AG ADR).
The best stock recommendation documented was for NVS (NOVARTIS AG ADR) at 3/28/2023. The price target of $113.35 was fulfilled within 505 days with a profit of $30.45 (36.73%) receiving and performance score of 0.73.

Average potential price target upside

GSK GlaxoSmithKline PLC ADR NVS Novartis AG ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

17 days ago
(15-Nov-2024)

0/13 (0%)

$-19.36 (-47.20%)

Buy

$39.5

$5.37 (15.73%)

$53

20 days ago
(12-Nov-2024)

2/5 (40%)

$4 (11.27%)

368

Buy

$22.07

4 months 24 days ago
(08-Jul-2024)

0/14 (0%)

$-16.41 (-42.65%)

Hold

$44

$9.87 (28.92%)

$18.72

10 months 9 days ago
(23-Jan-2024)

1/14 (7.14%)

$5.42 (14.05%)

107

Hold

$19.52

$-14.61 (-42.81%)

$18.9

1 years 3 months 18 days ago
(14-Aug-2023)

0/3 (0%)

$-14.59 (-42.77%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Graham Parry is most bullish on?

Potential upside of $24.23 has been obtained for NVS (NOVARTIS AG ADR)

What Year was the first public recommendation made by Graham Parry?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?